본문 바로가기

본문 바로가기

Meet Us at ADA 2026

Meet Us at ADA 2026.

HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice
Presentation Number
1783-P
Session
Sunday General Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Dahae Lee, Ph.D /
Hanmi Pharm. Co., Ltd.
Protective Effects of HM17321, a Novel UCN2 Analog, on Obesity-Associated Musculoskeletal Diseases in Mouse Models
Presentation Number
1803-P
Session
Sunday General Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Hyunjoo Kwon, Ph.D /
Hanmi Pharm. Co., Ltd.
Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice
Presentation Number
2537-P
Session
ePoster Theater - Obesity Treatment: Comparisons, Outcomes, and Effects, Jun. 7 at 12:10~12:20 PM / Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Seon Myeong Lee /
Hanmi Pharm. Co., Ltd.
Cardiorenal protective effects of a CRFR2-selective UCN2 analog, HM17321, in spontaneously hypertensive rats (SHR)
Presentation Number
2538-P
Session
Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Seon Myeong Lee /
Hanmi Pharm. Co., Ltd.
Temporal Mechanistic Shifts Underlying Sustained Muscle Growth by HM17321 Revealed by Tissue Proteome Analysis
Presentation Number
2579-P
Session
Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Boram Kim, Ph.D /
Hanmi Pharm. Co., Ltd.
Cardioprotective Effects of HM17321, a Novel UCN2 Analog, in Rodent Heart Failure Models and a Translational Nonhuman Primate Model
Presentation Number
2872-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Byeongjin Ye, Ph.D /
Hanmi Pharm. Co., Ltd.
HM500197, a De Novo-Designed Long-Acting Peptide Myostatin Inhibitor, Improves Skeletal Muscle Mass and Body Composition in Diet-Induced Obese Mice
Presentation Number
3073-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Jaehyuk Choi, Ph.D /
Hanmi Pharm. Co., Ltd.
HM17321, a Novel UCN2 Analog, Improves Weight Loss Quality in Combination with Amylin Analogs in DIO Rats
Presentation Number
3078-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Yohan Kim /
Hanmi Pharm. Co., Ltd.

다시, 창조와 혁신으로

임성기 정신.
창조혁신의 정신.
이제, 다시,
새로운 도전에 나섭니다.

Focus on Making
Innovative Medicines

한미약품은 다양한 치료 영역을 포괄하는
탄탄한 R&D 인프라를 바탕으로
제약분야에서 혁신을 선도하고 있습니다.

비만/대사

비만, 대사 이상 관련 지방간염 등 다양한 작용기전
Best-in-class 신약 개발

View More

What We Make

ESG Report

한미약품의 ESG 경영은
'일상의 혁신'입니다.

View More

당신의 꿈이
한미약품의 미래입니다.
당신을 기다립니다.

Join Us